Enjoy complimentary customisation on priority with our Enterprise License!
The global migraine drugs market size is estimated to grow by USD 1,139.92 million at a CAGR of 6.05% between 2022 and 2027.
New classes of drugs with higher clinical efficacy, such as calcitonin gene-related peptide (CGRP) and monoclonal antibodies, are expected to provide growth momentum to the growth of the global migraine drugs market during the forecast period. A 37-amino acid peptide known as CGRP is abundantly found in the hypothalamus, thalamus, and cerebellum, as well as in sensory fibers and neurons that transmit pain at the trigeminal ganglia and dorsal root ganglia. The fact that episodic migraine episodes raise CGRP serum levels, that intravenous CGRP infusions set off attacks in migraineurs, and that CGRP concentrations in jugular vein blood increase during migraine headache attacks highlight the crucial function of this peptide in migraine. Additionally, CGRP serum level decreases with symptomatic relief of the headache. Over the past three years, four monoclonal antibodies (mAb) against CGRP have been approved for the treatment of migraines. The increasing approval of CGRP and monoclonal antibodies for the treatment of migraine will drive the growth of the global migraine drugs market during the forecast period.
Technavio has segmented the market into End-User, Type, and Geography.
It also includes an in-depth analysis of drivers, trends, and challenges.
To learn more about this report, Request Free Sample
The market share growth by the hospitals segment will be significant during the forecast period. The increasing prevalence and diagnosis of migraine and the increasing number of public and private specialty hospitals and clinic segments in this worldwide migraine medication market are expected to be influenced by clinics offering migraine medicines over the forecast period.
Get a glance at the market contribution of various segments View a PDF Sample
The hospitals segment was valued at USD 1,124.88 million in 2017. Large hospitals and clinics have modern healthcare infrastructure, which means that they're able to acquire large quantities of top-quality healthcare products and consumables in bulk. Several advancements in treatment are expected to drive the growth of the global migraine drugs market during the forecast period.
Preventive segment
One of the major type segments in the migraine drugs market is the preventive segment, which is a treatment of migraines that is aimed at reducing the attack frequency and the severity of migraine. Preventive prophylactic therapy includes the prescription of off-label and generic antihypertensives, including beta-blockers such as propranolol and atenolol. Preventive drugs are taken regularly, often daily, to reduce the severity or frequency of migraine. Preventive medications help in increasing the effectiveness of the symptom-relieving medicines used during migraine attacks. Some of the devices are used for the preventive treatment of migraines. The availability of such solutions is expected to fuel the growth of the global migraine therapeutics market during the forecast period. Therefore, such factors will propel the growth of the preventive segment in the global migraine drugs market during the forecast period.
Abortive segment
Another segment is an abortive segment, which is a treatment for migraine that's for pain-relieving medication. For abortive treatment, drugs are taken during migraine attacks, thereby helping to stop the symptoms. As soon as migraine symptoms appear, patients should start taking painkillers for the best outcome. Over time, there have become more migraine abortive treatments available. There are two types of abortive medication for migraines: specific and The specific treatment includes ergotamines and triptans. The abortive drugs that are taken under the prescription or guidance of the doctors will function as an acute treatment for migraine. Therefore, such factors will drive the growth of the abortive segment in the global migraine drugs market during the forecast period.
For more insights about the market share of various regions View PDF Sample now!
North America is estimated to contribute 37% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. North America is the major contributor of global migraine drugs. The presence of a well-established healthcare system that provides high-quality migraine therapeutics, primarily through its clinics and hospitals, is driving the migraine drugs market in North America. Another factor that will support the growth of the migraine medicines market in this area is rising healthcare expenditure in countries such as the United States and Canada. Alder Biopharmaceuticals, Amgen, Eli Lilly and Co., and Novartis are some of the largest companies in North America that sell migraine medicines. To increase the commercialization of migraine drugs in North America, there are several strategic partnerships between pharmaceutical companies. Such collaborations are likely to fuel the growth of the migraine therapeutics market in North America during the forecast period.
The outbreak of COVID-19 in 2020 and nationwide lockdowns had a negative impact on the growth of the regional migraine drugs market. However, owing to the large-scale vaccination drives conducted by the government across the region in the first half of 2021, the situation stabilized. The demand for migraine therapeutics recovered with the prevalence and diagnosis of migraine in the region. The demand for migraine drugs will be increased in the North American region when regular neurological treatment and therapy are resumed. Therefore, such factors will propel the growth of the migraine drugs market in the region during the forecast period.
Buy Now Full Report and Discover More
Vendors are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market vendors, including:
AbbVie Inc. - The company offers a migraine drug called QULIPTA atonement.
Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.
There are multiple factors influencing market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges.
The increase in the number of patients suffering from migraine is driving growth in the migraine drugs market. Migraine is a very common neurological condition globally. It is more common in North America, and migraine can also result from taking too many painkillers. The frequent use of some medications can lead to the development of a disabling condition termed medication-overuse headache (MOH). Lack of sleep, hunger, migraines, weather change, excess stimulation in the senses, and stress are some other triggers. Migraines usually start at a young age, or in early adulthood.
Moreover, Women are more susceptible to migraine and less responsive to migraine treatment. The female reproductive hormone estrogen plays a major role in causing migraine. Changes in the estrogen level have an effect on your brain cells. Demand for migraine treatment is expected to be increased due to the large number of patients who suffer from migraines worldwide. Therefore, the prevalence of migraine globally will drive the demand for migraine drugs, in turn, propel the global migraine drugs market during the forecast period.
The rising advances in migraine drugs are a primary trend in the migraine drugs market. Migraine drug manufacturers are increasingly focusing on producing more migraine-preventive drugs than migraine-treating drugs. They are aiming at stopping the migraine headache before it begins. Some migraine-preventive drugs affect brain chemicals and disable the chance of getting a migraine. There has been an emergence of various migraine drugs aimed at reducing the attack frequency and severity. Pharmacological migraine prevention has seen a few advances in recent years. Various drug classes are used for migraine prevention, and several clinical practice guidelines have been published across the world.
In recent years, advances in migraine research have led to the emergence of novel preventive migraine treatment methods. CGRP antagonists have emerged as a possible new preventive migraine treatment. The CGRP targets specific migraine mechanisms and is the first non-serotoninergic, migraine-specific drug without a vasoconstrictor action. It is also said to be suitable for patients with vascular diseases such as coronary artery disease and peripheral vascular disease. Therefore, the availability of such migraine preventive drugs is expected to drive the growth of the global migraine drugs market during the forecast period.
The lack of awareness and proper diagnosis of migraine is a major challenge in the migraine drugs market. There is a lack of awareness about the symptoms of migraine, especially among the youth. This makes it difficult for individuals to be diagnosed and treated properly. The lack of treatment may increase the incidence of the disease becoming chronic. Diseases such as chronic migraine are mostly undiagnosed or undertreated. Mostly, patients with chronic migraine consult physicians for headaches and receive headache subtype diagnoses at low rates. This may result in an inefficient treatment for the disease itself. In view of the need for appropriate diagnosis to design a suitable treatment program, this low rate of accurate diagnosis is one of the main barriers to optimum care.
Moreover, in developing countries, price sensitivity acts as a major barrier, which prevents individuals with chronic migraine from obtaining the required treatment. Consequently, the demand for migraine medicines is adversely affected by the lack of awareness, the lack of basic healthcare facilities, the high cost of hospitalization, and the low disposable income in some countries. Therefore, the lack of awareness and proper diagnosis of migraine is expected to adversely affect the global migraine market during the forecast period.
Buy Now Full Report and Discover More
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Migraine Drugs Market Customer Landscape
The migraine drugs market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.
|
Migraine Drugs Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
164 |
|
Base year |
2022 |
|
Historic period |
2017-2021 |
|
Forecast period |
2023-2027 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 6.05% |
|
Market growth 2023-2027 |
USD 1,139.92 million |
|
Market structure |
Fragmented |
|
YoY growth 2022-2023(%) |
5.42 |
|
Regional analysis |
North America, Europe, Asia, and the Rest of World (ROW) |
|
Performing market contribution |
North America at 37% |
|
Key countries |
US, Canada, Germany, China, and Japan |
|
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
Abbott Laboratories, AbbVie Inc., Amgen Inc., Amneal Pharmaceuticals Inc., AstraZeneca, Bausch Health Co. Inc., Bayer AG, Dr Reddys Laboratories Ltd., Eli Lilly and Co., Endo International Plc, GlaxoSmithKline Plc, H Lundbeck AS, Johnson and Johnson Services Inc., Merck KGaA, Neurelis Inc., Otsuka Holdings Co. Ltd., Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., and Winston Pharmaceuticals Ltd. |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
View Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by End-user
7 Market Segmentation by Type
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
Secondary sources
DATA ANALYSIS
Data Synthesis
Data Validation
REPORT WRITING
Qualitative
Quantitative
Certified ISO 9001 : 2015
We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.
We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.
Get lifetime access to our
Technavio Insights
Customized Report as per your Business Needs
Let us help you make report more suited to your requirements.
Get the report (PDF) sent to your email within minutes.
